Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Cannabis Investors Are Watching Herbal Dispatch (CSE:HERB) (click to learn more) AI Wellness Stock Targeting Massive Growth (CSE: ALEN.U) (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Abbvie CDR ABBV


Primary Symbol: T.ABBV

Healthcare Drug Manufacturers - Major
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis... see more

Current News (TSX:ABBV)

MAVIRET® receives Health Canada Approval for the Treatment of Acute Hepatitis C Virus

Canada NewsWire January 6, 2026

AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers

PR Newswire December 2, 2025

SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance

GlobeNewswire November 28, 2025

AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec

GlobeNewswire November 25, 2025

AbbVie to Present at the Piper Sandler 37th Annual Healthcare Conference

PR Newswire November 24, 2025

AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma

PR Newswire November 18, 2025

LUPRON DEPOT® new strength receives Health Canada Approval for the Treatment of Advanced Prostate Cancer

Canada NewsWire November 17, 2025

AbbVie Partners with Award-Winning Filmmaker on Film About the Dynamic and Resilient Lives of Those Living with Blood Cancer

PR Newswire November 14, 2025

AbbVie Announces 20 Recipients of Migraine Career Catalyst Award(TM)

PR Newswire November 13, 2025
View More News ››

Opinion & Analysis (TSX:ABBV)

Use stock volatility to invest in innovative oncology companies: JMP Security's Michael King Jr.

Gail Dutton October 15, 2015

Probe biotech's diverse subsectors for strong, undervalued companies: Van Leeuwenhoeck's Marcel Wijma

Gail Dutton July 2, 2015
View More Opinion ››

Bullboard Posts (TSX:ABBV)

AbbVie’s Payout Rhythm: What Recent Dates Reveal

If you're tracking ABBV dividend date, the latest quarterly payout of $1.64 per share was made on August 15, 2025, to shareholders...
EvansWilson - August 29, 2025

$XLO 52 Million in Cash and over 2 Billion ABBV

$XLO 52 Million in Cash and over 2 Billion in Milestone payments with $ABBV https://www.stocktitan.net/news/XLO/abb-vie-and-xilio...
10QKing - February 12, 2025

ABBV: Botox Boost, But Humira’s Decline Looms 🧬

ABBV is solid for now, especially with Botox driving growth in aesthetics. But Humira’s revenue is dropping fast due to biosimilars...
SmartBull65 - December 3, 2024

Incredible Value. ENTG at about 25% of One Years Revenue

.with revenues now demonstrating an upward Trajectory amd likely attaining profitability within a couple of quarters. May reportage for...
Wrywisdom - August 10, 2022

ONE DRUG PILL WIPES OUT COVID 19!

India's Ivermectin Blackout - Part V: The Secret Revealed ...   Sep 27, 2021 · By September 12, 2021...
zeropointenergy - October 6, 2021

what was the big drop ?? saw no news

what was the big drop ?? saw no news
plomar2011 - September 1, 2021
View more Bullboard ››

Viridian Metals Inc.

Viridian Metals Inc.

Viridian Metals Inc. is a Canadian company engaged in generative exploration for critical metals, with a primary focus on ...
View More »

Podcasts